Skip Navigation



JAC Advance Access published online on April 25, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg245
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/6/1419    most recent
dkg245v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Berthet, N.
Right arrow Articles by Brugère, J.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berthet, N.
Right arrow Articles by Brugère, J.-F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Brief report

In vitro susceptibility of Aspergillus spp. clinical isolates to albendazole

N. Berthet 1, O. Faure 2, A. Bakri 3, P. Ambroise-Thomas 4, R. Grillot 4, J.-F. Brugère 1*

1 Laboratoire ‘Interactions Cellulaires Parasite-Hôte' ICPH, Faculté de Médecine et Pharmacie, Université Joseph Fourier, F-38706 La Tronche
2 Service de Parasitologie-Mycologie, CHU, BP217, F-38043 Grenoble
3 Formulation et ingénierie pharmaceutique, Code GEPRA, INSERM 008, Faculté de Pharmacie, Université Joseph Fourier, F-38706 La Tronche, France
4 Laboratoire ‘Interactions Cellulaires Parasite-Hôte' ICPH, Faculté de Médecine et Pharmacie, Université Joseph Fourier, F-38706 La Tronche; Service de Parasitologie-Mycologie, CHU, BP217, F-38043 Grenoble

* Corresponding author. E-mail: Jean-Francois.Brugere{at}ujf-grenoble.fr.

Received 25 October 2002 ; revised 1 December 2002 ; accepted 12 March 2003

Abstract

The in vitro antifungal activity of albendazole, a benzimidazole widely used as an antihelmintic drug in humans, was investigated and assessed for its activity against Aspergillus spp. Forty-eight isolates, representing the most frequent species found in human pathology [Aspergillus fumigatus (n = 27), Aspergillus flavus (n = 10), Aspergillus terreus (n = 7), Aspergillus nidulans (n = 3) and Aspergillus niger (n = 1)], and one quality control strain (A. niger ATCC 9804 83435) were tested according to the NCCLS M38-P methodology for moulds. All the strains were susceptible to albendazole, with homogeneous MICs for each species; three strains were resistant to itraconazole.

Keywords: drug susceptibility, benzimidazole, antifungal
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
W. J. Steinbach, J. R. Perfect, W. A. Schell, T. J. Walsh, and D. K. Benjamin Jr.
In Vitro Analyses, Animal Models, and 60 Clinical Cases of Invasive Aspergillus terreus Infection
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3217 - 3225.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.